Analysis reveals KPC-71 and NDM contribute to CFDC resistance in carbapenem-resistant Klebsiella pneumoniae, suggesting tailored treatment may be needed.
Key Points
Low-level cefiderocol resistance in carbapenem-resistant Klebsiella pneumoniae was observed in 7.6% of clinical isolates, signaling a critical public health trend.
Phylogenetic analysis categorized isolates into clusters based on genetic profiles, highlighting the role of KPC-71 and NDM in resistance mechanisms.
Testing showed avibactam improved cefiderocol effectiveness, reducing MICs significantly in KPC-producing strains, yet had limited effects on NDM strains.
The findings stress the importance of understanding resistance mechanisms to develop targeted strategies against emerging KPC variants in clinical settings.